Its good they have toned down from "buy out" to "licensing", so less of CRs and get a powerfull pharma to back you and then buy out or royalty, looks like this will have a sustained share price appreciation if all goes well...
The global model for biotech commercialisation is to out-license the technology to Big Pharma in Phase 1b/2 trials • Conducting Phase 3 trials, obtaining FDA approval for the product not within the remit of biotech • Out-licensing is highly dependent upon demonstrating safety in Phase 1 and convincing signals of efficacy in Phase 1b/2 • Licensing deals are generally structured with an up-front cash payment, payments upon reaching certain development milestones such as entering Phase 3 trials, payment on FDA approval of the drug, and royalties on net sales when the drug is on the market
IMU Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)